Homeostatic  ||| S:0 E:12 ||| JJ
responses  ||| S:12 E:22 ||| NNS
of  ||| S:22 E:25 ||| IN
colonic  ||| S:25 E:33 ||| CD
LGR5+  ||| S:33 E:39 ||| CD
stem  ||| S:39 E:44 ||| NN
cells  ||| S:44 E:50 ||| NNS
following  ||| S:50 E:60 ||| VBG
acute  ||| S:60 E:66 ||| JJ
in  ||| S:66 E:69 ||| IN
vivo  ||| S:69 E:74 ||| JJ
exposure  ||| S:74 E:83 ||| NN
to  ||| S:83 E:86 ||| TO
a  ||| S:86 E:88 ||| DT
genotoxic  ||| S:88 E:98 ||| JJ
carcinogen  ||| S:98 E:109 ||| NN
Perturbations  ||| S:109 E:123 ||| NNS
in  ||| S:123 E:126 ||| IN
DNA  ||| S:126 E:130 ||| NNP
damage ||| S:130 E:136 ||| NN
,  ||| S:136 E:138 ||| ,
DNA  ||| S:138 E:142 ||| NNP
repair ||| S:142 E:148 ||| NN
,  ||| S:148 E:150 ||| ,
apoptosis  ||| S:150 E:160 ||| NN
and  ||| S:160 E:164 ||| CC
cell  ||| S:164 E:169 ||| NN
proliferation  ||| S:169 E:183 ||| NN
in  ||| S:183 E:186 ||| IN
the  ||| S:186 E:190 ||| DT
base  ||| S:190 E:195 ||| NN
of  ||| S:195 E:198 ||| IN
the  ||| S:198 E:202 ||| DT
crypt  ||| S:202 E:208 ||| NN
where  ||| S:208 E:214 ||| WRB
stem  ||| S:214 E:219 ||| JJ
cells  ||| S:219 E:225 ||| NNS
reside  ||| S:225 E:232 ||| NNS
are  ||| S:232 E:236 ||| VBP
associated  ||| S:236 E:247 ||| VBN
with  ||| S:247 E:252 ||| IN
colorectal  ||| S:252 E:263 ||| JJ
cancer  ||| S:263 E:270 ||| NN
( ||| S:270 E:271 ||| -LRB-
CRC ||| S:271 E:274 ||| NNP
)  ||| S:274 E:276 ||| -RRB-
initiation  ||| S:276 E:287 ||| NN
and  ||| S:287 E:291 ||| CC
progression ||| S:291 E:302 ||| NN
.  ||| S:302 E:304 ||| .
Although  ||| S:304 E:313 ||| IN
the  ||| S:313 E:317 ||| DT
transformation  ||| S:317 E:332 ||| NN
of  ||| S:332 E:335 ||| IN
leucine-rich  ||| S:335 E:348 ||| NNP
repeat-containing  ||| S:348 E:366 ||| NNP
G  ||| S:366 E:368 ||| NNP
protein-coupled  ||| S:368 E:384 ||| NNP
receptor  ||| S:384 E:393 ||| VBD
5  ||| S:393 E:395 ||| CD
( ||| S:395 E:396 ||| -LRB-
Lgr5 ||| S:396 E:400 ||| NNP
) ||| S:400 E:401 ||| -RRB-
( ||| S:401 E:402 ||| -LRB-
+ ||| S:402 E:403 ||| NNP
)  ||| S:403 E:405 ||| -RRB-
cells  ||| S:405 E:411 ||| NNS
is  ||| S:411 E:414 ||| VBZ
an  ||| S:414 E:417 ||| DT
extremely  ||| S:417 E:427 ||| RB
efficient  ||| S:427 E:437 ||| JJ
route  ||| S:437 E:443 ||| NN
towards  ||| S:443 E:451 ||| IN
initiating  ||| S:451 E:462 ||| VBG
small  ||| S:462 E:468 ||| JJ
intestinal  ||| S:468 E:479 ||| JJ
adenomas ||| S:479 E:487 ||| NN
,  ||| S:487 E:489 ||| ,
the  ||| S:489 E:493 ||| DT
role  ||| S:493 E:498 ||| NN
of  ||| S:498 E:501 ||| IN
Lgr5 ||| S:501 E:505 ||| NNP
( ||| S:505 E:506 ||| -LRB-
+ ||| S:506 E:507 ||| NNP
)  ||| S:507 E:509 ||| -RRB-
cells  ||| S:509 E:515 ||| NNS
in  ||| S:515 E:518 ||| IN
CRC  ||| S:518 E:522 ||| NNP
pathogenesis  ||| S:522 E:535 ||| NN
has  ||| S:535 E:539 ||| VBZ
not  ||| S:539 E:543 ||| RB
been  ||| S:543 E:548 ||| VBN
well  ||| S:548 E:553 ||| RB
investigated ||| S:553 E:565 ||| VBN
.  ||| S:565 E:567 ||| .
Therefore ||| S:567 E:576 ||| RB
,  ||| S:576 E:578 ||| ,
we  ||| S:578 E:581 ||| PRP
further  ||| S:581 E:589 ||| RB
characterized  ||| S:589 E:603 ||| VBN
the  ||| S:603 E:607 ||| DT
properties  ||| S:607 E:618 ||| NNS
of  ||| S:618 E:621 ||| IN
colonic  ||| S:621 E:629 ||| CD
Lgr5 ||| S:629 E:633 ||| CD
( ||| S:633 E:634 ||| -LRB-
+ ||| S:634 E:635 ||| NNP
)  ||| S:635 E:637 ||| -RRB-
cells  ||| S:637 E:643 ||| NNS
compared  ||| S:643 E:652 ||| VBN
to  ||| S:652 E:655 ||| TO
differentiated  ||| S:655 E:670 ||| VB
cells  ||| S:670 E:676 ||| NNS
in  ||| S:676 E:679 ||| IN
Lgr5-EGFP-IRES-creER ||| S:679 E:699 ||| NNP
( ||| S:699 E:700 ||| -LRB-
T2 ||| S:700 E:702 ||| NNP
)  ||| S:702 E:704 ||| -RRB-
knock-in  ||| S:704 E:713 ||| JJ
mice  ||| S:713 E:718 ||| NNS
at  ||| S:718 E:721 ||| IN
the  ||| S:721 E:725 ||| DT
initiation  ||| S:725 E:736 ||| JJ
stage  ||| S:736 E:742 ||| NN
of  ||| S:742 E:745 ||| IN
carcinogen  ||| S:745 E:756 ||| JJ
azoxymethane  ||| S:756 E:769 ||| NNS
( ||| S:769 E:770 ||| -LRB-
AOM ||| S:770 E:773 ||| NNP
) ||| S:773 E:774 ||| -RRB-
-induced  ||| S:774 E:783 ||| JJ
tumorigenesis  ||| S:783 E:797 ||| NNS
using  ||| S:797 E:803 ||| VBG
a  ||| S:803 E:805 ||| DT
quantitative  ||| S:805 E:818 ||| JJ
immunofluorescence  ||| S:818 E:837 ||| JJ
microscopy  ||| S:837 E:848 ||| JJ
approach ||| S:848 E:856 ||| NN
.  ||| S:856 E:858 ||| .
At  ||| S:858 E:861 ||| IN
12  ||| S:861 E:864 ||| CD
and  ||| S:864 E:868 ||| CC
24h  ||| S:868 E:872 ||| CD
post-AOM  ||| S:872 E:881 ||| JJ
treatment ||| S:881 E:890 ||| NN
,  ||| S:890 E:892 ||| ,
colonic  ||| S:892 E:900 ||| FW
Lgr5 ||| S:900 E:904 ||| FW
( ||| S:904 E:905 ||| -LRB-
+ ||| S:905 E:906 ||| NNP
)  ||| S:906 E:908 ||| -RRB-
stem  ||| S:908 E:913 ||| VBP
cells  ||| S:913 E:919 ||| NNS
( ||| S:919 E:920 ||| -LRB-
GFP ||| S:920 E:923 ||| NNP
( ||| S:923 E:924 ||| -LRB-
high ||| S:924 E:928 ||| JJ
) ||| S:928 E:929 ||| -RRB-
)  ||| S:929 E:931 ||| -RRB-
were  ||| S:931 E:936 ||| VBD
preferentially  ||| S:936 E:951 ||| VBN
damaged  ||| S:951 E:959 ||| VBN
by  ||| S:959 E:962 ||| IN
carcinogen ||| S:962 E:972 ||| NN
,  ||| S:972 E:974 ||| ,
exhibiting  ||| S:974 E:985 ||| VBG
a  ||| S:985 E:987 ||| DT
4.7-fold  ||| S:987 E:996 ||| JJ
induction  ||| S:996 E:1006 ||| NN
of  ||| S:1006 E:1009 ||| IN
apoptosis  ||| S:1009 E:1019 ||| VBG
compared  ||| S:1019 E:1028 ||| VBN
to  ||| S:1028 E:1031 ||| TO
differentiated  ||| S:1031 E:1046 ||| VB
( ||| S:1046 E:1047 ||| -LRB-
GFP ||| S:1047 E:1050 ||| NNP
( ||| S:1050 E:1051 ||| -LRB-
neg ||| S:1051 E:1054 ||| LS
) ||| S:1054 E:1055 ||| -RRB-
)  ||| S:1055 E:1057 ||| -RRB-
cells ||| S:1057 E:1062 ||| NNS
.  ||| S:1062 E:1064 ||| .
Furthermore ||| S:1064 E:1075 ||| RB
,  ||| S:1075 E:1077 ||| ,
with  ||| S:1077 E:1082 ||| IN
respect  ||| S:1082 E:1090 ||| NN
to  ||| S:1090 E:1093 ||| TO
DNA  ||| S:1093 E:1097 ||| NNP
repair ||| S:1097 E:1103 ||| NN
,  ||| S:1103 E:1105 ||| ,
O ||| S:1105 E:1106 ||| NNP
( ||| S:1106 E:1107 ||| -LRB-
6 ||| S:1107 E:1108 ||| CD
) ||| S:1108 E:1109 ||| -RRB-
-methylguanine  ||| S:1109 E:1124 ||| JJ
DNA  ||| S:1124 E:1128 ||| NN
methyltransferase  ||| S:1128 E:1146 ||| NNS
( ||| S:1146 E:1147 ||| -LRB-
MGMT ||| S:1147 E:1151 ||| NNP
)  ||| S:1151 E:1153 ||| -RRB-
expression  ||| S:1153 E:1164 ||| NN
was  ||| S:1164 E:1168 ||| VBD
preferentially  ||| S:1168 E:1183 ||| JJ
induced  ||| S:1183 E:1191 ||| NNS
( ||| S:1191 E:1192 ||| -LRB-
by  ||| S:1192 E:1195 ||| IN
18.5-fold ||| S:1195 E:1204 ||| CD
)  ||| S:1204 E:1206 ||| -RRB-
in  ||| S:1206 E:1209 ||| IN
GFP ||| S:1209 E:1212 ||| NNP
( ||| S:1212 E:1213 ||| -LRB-
high ||| S:1213 E:1217 ||| JJ
)  ||| S:1217 E:1219 ||| -RRB-
cells  ||| S:1219 E:1225 ||| NNS
at  ||| S:1225 E:1228 ||| IN
24h  ||| S:1228 E:1232 ||| CD
post-AOM  ||| S:1232 E:1241 ||| JJ
treatment  ||| S:1241 E:1251 ||| NN
compared  ||| S:1251 E:1260 ||| VBN
to  ||| S:1260 E:1263 ||| TO
GFP ||| S:1263 E:1266 ||| NNP
( ||| S:1266 E:1267 ||| -LRB-
neg ||| S:1267 E:1270 ||| LS
)  ||| S:1270 E:1272 ||| -RRB-
differentiated  ||| S:1272 E:1287 ||| JJ
cells ||| S:1287 E:1292 ||| NNS
.  ||| S:1292 E:1294 ||| .
This  ||| S:1294 E:1299 ||| DT
corresponded  ||| S:1299 E:1312 ||| NN
with  ||| S:1312 E:1317 ||| IN
a  ||| S:1317 E:1319 ||| DT
4.3-fold  ||| S:1319 E:1328 ||| JJ
increase  ||| S:1328 E:1337 ||| NN
in  ||| S:1337 E:1340 ||| IN
cell  ||| S:1340 E:1345 ||| NN
proliferation  ||| S:1345 E:1359 ||| NN
in  ||| S:1359 E:1362 ||| IN
GFP ||| S:1362 E:1365 ||| NNP
( ||| S:1365 E:1366 ||| -LRB-
high ||| S:1366 E:1370 ||| JJ
)  ||| S:1370 E:1372 ||| -RRB-
cells ||| S:1372 E:1377 ||| NNS
.  ||| S:1377 E:1379 ||| .
These  ||| S:1379 E:1385 ||| DT
data  ||| S:1385 E:1390 ||| NNS
suggest  ||| S:1390 E:1398 ||| VBP
that  ||| S:1398 E:1403 ||| IN
Lgr5 ||| S:1403 E:1407 ||| NNP
( ||| S:1407 E:1408 ||| -LRB-
+ ||| S:1408 E:1409 ||| NNP
)  ||| S:1409 E:1411 ||| -RRB-
stem  ||| S:1411 E:1416 ||| VBP
cells  ||| S:1416 E:1422 ||| NNS
uniquely  ||| S:1422 E:1431 ||| RB
respond  ||| S:1431 E:1439 ||| VB
to  ||| S:1439 E:1442 ||| TO
alkylation-induced  ||| S:1442 E:1461 ||| JJ
DNA  ||| S:1461 E:1465 ||| NN
damage  ||| S:1465 E:1472 ||| NN
by  ||| S:1472 E:1475 ||| IN
upregulating  ||| S:1475 E:1488 ||| JJ
DNA  ||| S:1488 E:1492 ||| NN
damage  ||| S:1492 E:1499 ||| NN
repair ||| S:1499 E:1505 ||| NN
,  ||| S:1505 E:1507 ||| ,
apoptosis  ||| S:1507 E:1517 ||| NN
and  ||| S:1517 E:1521 ||| CC
cell  ||| S:1521 E:1526 ||| NN
proliferation  ||| S:1526 E:1540 ||| NN
compared  ||| S:1540 E:1549 ||| VBN
to  ||| S:1549 E:1552 ||| TO
differentiated  ||| S:1552 E:1567 ||| VB
cells  ||| S:1567 E:1573 ||| NNS
in  ||| S:1573 E:1576 ||| IN
order  ||| S:1576 E:1582 ||| NN
to  ||| S:1582 E:1585 ||| TO
maintain  ||| S:1585 E:1594 ||| VB
genomic  ||| S:1594 E:1602 ||| JJ
integrity ||| S:1602 E:1611 ||| NN
.  ||| S:1611 E:1613 ||| .
These  ||| S:1613 E:1619 ||| DT
findings  ||| S:1619 E:1628 ||| NNS
highlight  ||| S:1628 E:1638 ||| VB
the  ||| S:1638 E:1642 ||| DT
mechanisms  ||| S:1642 E:1653 ||| NNS
by  ||| S:1653 E:1656 ||| IN
which  ||| S:1656 E:1662 ||| WDT
colonic  ||| S:1662 E:1670 ||| VBD
Lgr5 ||| S:1670 E:1674 ||| CD
( ||| S:1674 E:1675 ||| -LRB-
+ ||| S:1675 E:1676 ||| NNP
)  ||| S:1676 E:1678 ||| -RRB-
stem  ||| S:1678 E:1683 ||| VBP
cells  ||| S:1683 E:1689 ||| NNS
respond  ||| S:1689 E:1697 ||| VBP
to  ||| S:1697 E:1700 ||| TO
cancer-causing  ||| S:1700 E:1715 ||| JJ
environmental  ||| S:1715 E:1729 ||| JJ
factors ||| S:1729 E:1736 ||| NNS
.  ||| S:1736 E:1738 ||| .
